What's Happening?
Duopharma Biotech Berhad reported a 14.5% increase in revenue for FY2025, reaching RM931.69 million, driven by strong demand and a surge in insulin supply. The company also saw a 43.6% rise in Profit Before Tax, surpassing RM100 million for the first
time. Duopharma Biotech is focusing on expanding its product portfolio and manufacturing capacity to support Malaysia's pharmaceutical self-reliance, aligning with national policies like the 13th Malaysia Plan and the New Industrial Master Plan 2030. The company aims to enhance the production of biologics, generics, and Halal medicines.
Why It's Important?
Duopharma Biotech's growth and strategic focus on manufacturing capacity are vital for Malaysia's healthcare ecosystem, ensuring reliable access to locally-manufactured medicines. The company's efforts support national priorities for pharmaceutical self-reliance, reducing dependency on imports and enhancing the country's ability to meet domestic healthcare needs. This aligns with government policies promoting domestic manufacturing and self-reliance in pharmaceutical supply chains, which are crucial for economic stability and public health resilience.
What's Next?
Duopharma Biotech plans to continue expanding its product portfolio, focusing on non-communicable and chronic conditions. The company will also enhance its manufacturing capacity to support domestic and international markets. With ongoing contracts to supply pharmaceutical products to the Ministry of Health, Duopharma Biotech is well-positioned to play a key role in Malaysia's healthcare sector. The company's strategic initiatives are expected to contribute to the country's long-term goals of pharmaceutical self-reliance and economic growth.
